Frontlight ResearchEarly access
TerminatedPhase 2
The Effects of Suvorexant on Sleep, Stress, and Cue-reactivity in Methamphetamine Use Disorder
Key facts
- Who runs it
- The University of Texas Health Science Center, Houston
- Where
- Houston, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 2
- People taking part
- 7 people enrolled
- Started
- 9 Mar 2023
- Ended
- 28 Mar 2024
- Type of study
- Interventional, 2 groups
- Treatments tested
- suvorexant (SUVO)
- Placebo
- Record updated
- 29 April 2025
- Why it stopped
- Lack of enrollment
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Meet DSM-5 criteria for MA use disorder
- Be fluent in English and able to understand the consent form
Who cannot take part
- Are currently taking medications with known drug interactions with SUVO (e.g., MAO inhibitors, anticonvulsants, haloperidol, phenothiazines, anesthetics, and any sedative)
- Have an alcohol use disorder or report binge drinking (>7 drinks for women and >14 drinks for men)
- Have a greater than mild substance use disorder on any other illicit substance
- Have any medical conditions contraindicating SUVO (e.g., severe pulmonary disease, severe cardiovascular disease or clinically abnormal ECG, severe liver or kidney disease, seizure disorder, or sleep disorder - particularly narcolepsy)
- Have a current DSM-5 psychiatric disorder or neurological disease requiring on-going treatment that would make participation unsafe
- Have history of seizure disorder
- Are pregnant or breast feeding
- BMI > 30 (women only)
- Have a head injury with loss of consciousness in the last 5 years
Where in United States
- The University of Texas Health Science Center at HoustonHouston, United States
About the trial
What the trial wants to find out
The purpose of this study is to determine the effects of SUVO on sleep, stress, and cue reactivity/craving and to evaluate the preliminary safety and side effects profile of suvorexant (SUVO)
The 2 groups in the trial
- 1 week Placebo, then 1 week suvorexant (SUVO)Treatment being tested
After 1 week of placebo treatment there will be 1 week of wash out period before start of study medication
Treatment: suvorexant (SUVO) and Placebo
- 1 week suvorexant (SUVO), then 1 week PlaceboTreatment being tested
After 1 week of SUVO treatment there will be 1 week of wash out period before start of placebo
Treatment: suvorexant (SUVO) and Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 29 April 2025